Woolsey Pharmaceuticals’ Financing Is Oversubscribed; Two Board Members Named

NEW YORK, NY – March 11, 2020 – Woolsey Pharmaceuticals announced today that it completed a round of financing that will fund operations through the completion of a planned clinical study. The amount was not disclosed but the financing was substantially oversubscribed, according to company officials.

The Company also announced the appointment of two outside board members, David Epstein and Dr. Claude Piché.

David R. Epstein has more than 25 years of extensive drug development, deal making, commercialization, and leadership experience on a global scale. From 2010 to mid-2016 he served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG 

Over the course of his career, David led the development and commercialization of more than 30 new molecular entities, including major breakthroughs such as Glivec®, Tasigna®, Gilenya®, Afinitor®, Cosentyx®, and Entresto®. His teams developed three Prix Galien award winners and he has developed several CEOs. He was named by FierceBiotech as one of the “25 most influential people in biopharma.”

David holds a B.S. in pharmacy from Rutgers University College of Pharmacy (1984) and an M.B.A. in finance and marketing from the Columbia University Graduate School of Business (1987).

Dr. Claude Piché is a seasoned bioscience executive, board member and investor with over 25 years of hands-on operational experience in developing and commercializing pharmaceuticals, vaccines, medical devices and diagnostics.

Dr. Piché is a co-founder and the President and CEO of Locemia Solutions. At Locemia, he led the creation and development of Baqsimi®, a needle-free repurposed rescue treatment for severe hypoglycemia; the product was acquired by Eli Lilly in 2015. Prior to Locemia, Dr. Piché worked at private, public, and startup biopharmaceutical companies with hands-on experience in research, regulatory affairs, marketing, operations and, business development.

Dr. Piché holds degrees from the University of Saskatchewan (DVM) and the University of Calgary (MSc). He is the author or co-author of over 30 peer reviewed scientific publications and over 40 scientific abstracts and presentations and is a co-inventor on several patent applications.


New York-based Woolsey Pharmaceuticals is a single-drug entity focused on the treatment of rare, neurodegenerative diseases with its compound BRAVYL (Fasudil).


Embark Healthcare

Sven Jacobson